Ons wil graag hê dat jy deel word van ons gemeenskap. Sluit aan by ons Discord om met ons en ander lede te skakel!

Ticker
COLO-B.CO

Price
797.20
Stock movement up
+6.80 (0.86%)
Company name
Coloplast A/S
Exchange
(CO
,
Currency
DKK
)
Sector
Healthcare >
Medical Instruments & Supplies
Markkapitalisasie
165.29B
Ondernemingswaarde
194.63B
Prys/Verkope
6.12
Prys/Boek
9.21
Dividendopbrengs
-
Dividendgroei
-
Groei jare
-
FCF uitbetaling
320.65%
Agterlopende P/E
32.72
Volgende P/E
29.24
PEG
-
EPS groei
4.33%
1 jaar opbrengs
4.26%
3 jaar opbrengs
-9.92%
5 jaar opbrengs
0.53%
10 jaar opbrengs
4.44%
Laaste opgedateer: 2024-12-21

DIVIDENDE

COLO-B.CO betaal nie dividende nie of geen data is ontvang nie

WAARDERING

Waarderingsverhoudings

Loading...
Waarderingsverhoudings gegewens
Agterlopende P/E32.72
Prys tot OCF59.76
Prys tot FCF112.29
Prys tot EBITDA37.96
EV tot EBITDA44.70

Waardering (Verkope/Boekwaarde)

Loading...
Waardering (Verkope/Boekwaarde) gegewens
Prys tot verkope6.12
Prys tot Boekwaarde9.21
EV tot verkope7.20

FINANSIËLE

Per aandeel

Loading...
Per aandeel gegewens
Huidige aandeeltelling207.34M
EPS (TTM)22.45
FCF per aandeel (TTM)6.54

Inkomstestaat

Loading...
Inkomstestaat gegewens
Inkomste (TTM)27.03B
Bruto wins (TTM)18.27B
Bedryfsinkomste (TTM)7.37B
Netto inkomste (TTM)5.05B
EPS (TTM)22.45
EPS (1j vorentoe)27.26

Marges

Loading...
Marges gegewens
Bruto marge (TTM)67.59%
Bedryfsmarge (TTM)27.25%
Winsgrens (TTM)18.69%

Balansstaat

Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Balansstaat gegewens
Kontant788.00M
Netto debiteure4.67B
Totale bedryfsbates10.44B
Klandisiewaarde19.38B
Ontasbare bates10.96B
Eiendom, aanleg en toerusting13.27B
Totale bates48.07B
Rekeninge betaalbaar1.52B
Kort/huidige langtermynskuld22.63B
Totale bedryfslaste10.20B
Totale laste30.13B
Aandeelhouersbelang17.94B
Netto tasbare bates0.00

Kontantvloei

Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Kontantvloei gegewens
Bedryfskontantvloei (TTM)2.77B
Kapitale uitgawes (TTM)1.29B
Vrye kontantvloei (TTM)1.47B
Dividende betaal (TTM)4.72B

Finansiële opbrengste

Loading...
Skep asseblief 'n gratis rekening of meld aan om toegang tot hierdie grafiek te kry
Finansiële opbrengste gegewens
Opbrengs op ekwiteit28.16%
Opbrengs op bates10.51%
Opbrengs op belegde kapitaal12.60%
Kontant opbrengs op belegde kapitaal3.67%

AANDELE INLIGTING

Aandele grafiek

Loading...
Aandele prys data
Open791.60
Daaglikse hoog799.20
Daaglikse laag786.60
Daaglikse volume333K
Hoogtepunt van alle tye1182.50
1j analiseraaming926.10
Beta0.34
EPS (TTM)22.45
Dividend per aandeel-
Ex-dividend datum6 Dec 2024
Volgende verdienste datum4 Feb 2025

Afwaartse potensiaal

Loading...
Afwaartse potensiaal gegewens
COLO-B.COS&P500
Huidige prysdaling vanaf die hoogste punt van alle tye-32.58%-2.74%
Hoogste prysdaling-43.67%-56.47%
Datum van hoogste daling28 Oct 19949 Mar 2009
Gemiddelde daling vanaf hoogtepunt-11.73%-11.13%
Gemiddelde tyd tot nuwe hoogtepunt16 days12 days
Maksimum tyd tot nuwe hoogtepunt854 days1805 days
MAATSKAPPY BESONDERHEDE
COLO-B.CO (Coloplast A/S) company logo
Markkapitalisasie
165.29B
Markkapitalisasie kategorie
Large-cap
Beskrywing
Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
Werknemers
16639
Beleggerverhoudings
-
CEO
Land
Denmark
Stad
Aandele tipe
-
CCC status
-
Dividendfrekwensie
-
GEBEURE EN AANBIEDINGS
GebeureAanbiedings
Loading...
VERSTAAN DIE BESIGHEID
Loading...
MAATSKAPPY NUUS
Alle nuusPersvrystellings
Today, 5 December 2024, Coloplast A/S held its Annual General Meeting, at which the following resolutions were adopted: The annual report for the financial year 2023/24 was approved.Distribution of ye...
5 Desember 2024
The divestment is part of a strategic initiative to simplify business operations and improve profitability in the Advanced Wound Care business area. Revenue from the core Skin Care business amounted t...
4 Desember 2024
On 14 November 2024, the U.S. Centers for Medicare & Medicaid Services (CMS) issued a final Local Coverage Determination (LCD)1 policy regarding skin substitute grafts/cellular and tissue-based produc...
14 November 2024
The Annual General Meeting of Coloplast A/S will be held onThursday, 5 December 2024 at 3:30 pm CETat the premises of Coloplast A/S, Holtedam 3 in Humlebæk (the Aage Louis-Hansen Auditorium), Humlebæk...
12 November 2024
Coloplast AS (CLPBF) reports robust financial performance with 8% organic growth and strategic product launches, despite facing supply disruptions and competitive pressures.
6 November 2024
Coloplast A/S - Annual Report 2023/24 & Remuneration Report 2023/24 FY 2023/24 organic growth of 8% and 27% EBIT margin1. Reported revenue in DKK grew 10% to DKK 27,030 million. Organic growth rates b...
5 November 2024
2023/24 Announcement of full-year financial results 1 October 2023 - 30 September 2024 Coloplast delivered Q4 organic growth of 8% and an EBIT margin1 of 26%, which was negatively impacted by extraord...
5 November 2024
Coloplast expands Executive Leadership Team Today, the Board of Directors have decided to expand the Coloplast Executive Leadership Team (ELT) with immediate effect. “We have entered the final year of...
5 November 2024
Earnings preview of key companies reporting this week and what to look out for.
1 November 2024
Tuesday, 5 November 2024 at 11.00 – 12.00 CETIn connection with the publication of Coloplast's interim financial results for FY 2023/24 the company will host a conference call to present the financial...
21 Oktober 2024
Volgende bladsy